Compare Amcor PLC (AMCR) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Hims and Hers Health Inc — how do they compare? Amcor PLC trades at $43.45 (market cap $19.96B), while Hims and Hers Health Inc trades at $34.14 (market cap $7.96B). The key difference: Amcor PLC is far larger — about 2.5× Hims and Hers Health Inc's market cap, and Amcor PLC pays a 6.02% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| AMCR | HIMS | |
|---|---|---|
Market Cap | $19.96B | $7.96B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $66.18 |
52-Week Low | $36.69 | $14.52 |
Enterprise Value | $35.08B | $8.34B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
Hims & Hers Health trades at $34.38, down 3.02% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights expansion in weight-loss therapies and a $400 million JPMorgan facility for financial flexibility, as the stock recovers from earlier regulatory concerns.
The outlook is cautiously optimistic, driven by growth in GLP-1 products and international expansion, but high valuation ratios and projected 2026 losses pose risks. Analyst consensus is a 'Hold' with a $33.57 price target, suggesting limited near-term upside from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
